Ipamorelin

What it is

Ipamorelin is summarized here from the public peptide research file, in this site's own wording. Selective ghrelin-receptor agonist ("growth hormone secretagogue"). The material sold on this site is a research vial, not a branded finished drug, and it is not for human or veterinary use.

Regulatory status

Non-FDA-approved peptide sold in the wellness/gray market. Not eligible for routine 503A compounding, because its 503A nomination was withdrawn Still on FDA's 503B Category 2 list Prohibited at all times in sport under the WADA list, which covers growth hormone secretagogues including ipamorelin

What the research shows

The headline finding recorded for it: Human data are limited to short pharmacology studies; benefit for recovery or body composition is unproven. Clinical development for post-operative ileus did not produce an approved product, and there are no controlled human trials supporting the marketed recovery or body-composition uses. Human data are limited to short studies of growth hormone release and one phase 2 ileus trial that missed its endpoint, and the marketed recovery and body-composition claims rest on animal and laboratory work. Ipamorelin is an experimental five-amino acid peptide that acts as a ghrelin mimic, developed years ago under the code NNC 26-0161 but never marketed as a drug. It is discussed in wellness write-ups and research-supply channels and promoted for recovery, body composition, and sleep, often paired with a GHRH analog such as CJC-1295 or sermorelin. Ipamorelin activates the growth hormone secretagogue receptor, the same receptor the hunger hormone ghrelin uses, which triggers the pituitary to release growth hormone in pulses. In laboratory work it is described as relatively "selective," raising growth hormone with comparatively little effect on other hormones such as cortisol and prolactin. In conscious swine, it released GH without raising ACTH or cortisol, while GHRP-6 and GHRP-2 raised both. Because growth hormone and GHRH signaling act together, ghrelin-mimic peptides are often combined with GHRH analogs. No published human randomized controlled trial tests ipamorelin with CJC-1295 as of September 2026. The marketed benefits are extrapolated from this growth-hormone effect. This describes the proposed mechanism, separate from proven outcomes.

Evidence limits

Evidence label in the source library: Low research. This page does not give a dose, a route, or a schedule. It is not medical advice and it is not instructions for the research vials on this site.

Reported actions

• Human data are limited to short pharmacology studies; benefit for recovery or body composition is unproven